TICKERNERD
Menu
NVCRNVCRHealthcare · Medical Devices

NVCR Stock Forecast: NovoCure Ltd. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$17
−2.47% on the day

The 7 Wall Street analysts covering NovoCure Ltd. hold a median 12-month price target of $25 — +47.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 13 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.0B
Ticker Nerd rank
94 / 100
Median analyst target
$25
Analysts covering
7
Total return, dividends reinvested
1W
+3.4%
1M
+9.0%
YTD
+31.1%
1Y
+46.2%
From 52W high
−15.2%
From 52W low
+69.0%
$10
$20
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NVCR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores NovoCure Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Aug 2026
94 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
92
Accruals
89
Issuance
84
Growth
84
Quality
77
Value
65
Momentum
45
Size
36
Volatility
31

Revisions (92): Analysts have, on balance, been raising their forecasts.

Volatility (31): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

NVCR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NVCR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26NVCRHigh $52Median $25Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says7 analysts
4 Buy3 Hold0 Sell
Low $17Median $25High $52

The green dot is the last close — the median target sits +47.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 July 2026WedbushMaintainsNeutral$18 → $20
23 July 2026HC Wainwright & Co.MaintainsBuy$46 → $52
13 July 2026JP MorganReinstatesNeutral$17
18 June 2026HC Wainwright & Co.ReiteratesBuy—
4 May 2026Wells FargoMaintainsEqual-Weight—
1 May 2026Evercore ISI GroupMaintainsOutperform—
16 Apr 2026WedbushReiteratesNeutral—
26 Feb 2026HC Wainwright & Co.MaintainsBuy—
12 Feb 2026HC Wainwright & Co.MaintainsBuy—
15 Jan 2026WedbushReiteratesNeutral—
13 Jan 2026HC Wainwright & Co.MaintainsBuy—
30 Oct 2025HC Wainwright & Co.MaintainsBuy—
27 Oct 2025JP MorganMaintainsNeutral—
25 July 2025Wells FargoDowngradeEqual-Weight—
8 July 2025Ladenburg ThalmannInitiatesBuy—
27 June 2025Piper SandlerReiteratesOverweight—
23 Apr 2025Piper SandlerMaintainsOverweight—
16 Apr 2025WedbushMaintainsNeutral—
10 Apr 2025JP MorganMaintainsNeutral—
14 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. NVCR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

NVCR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
6
Analysts cutting
0
Fundamentals

NovoCure Ltd. (NVCR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−13.9×

Cheaper than 94% of US stocks

Price / sales
2.8×

Cheaper than 44% of US stocks

Price / book
5.8×

Cheaper than 19% of US stocks

EV / EBITDA
−13.0×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
15.6%

Higher than 64% of US stocks

Earnings growth (YoY)
15.6%

Higher than 54% of US stocks

Gross margin
77.6%

Higher than 89% of US stocks

Operating margin
−5.8%

Higher than 27% of US stocks

Net margin
−21.2%

Higher than 15% of US stocks

Returns & dividend
Return on equity
−43.2%

Higher than 23% of US stocks

Return on assets
−9.3%

Higher than 27% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

NVCR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
NVCRNovoCure Ltd.$2.0B
94
ESTAEstablishment Labs Holdings, Inc.$2.2B
76
ALMRAlamar Biosciences, Inc. (California)$2.3B
4
BFLYButterfly Network, Inc.$2.4B
72
INSPInspire Medical Systems, Inc.$1.7B
77
UFPTUFP Technologies, Inc.$2.5B
75
TNDMTandem Diabetes Care, Inc.$1.6B
59

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own NovoCure Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NVCR news & analysis

Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet

Zacks Investment Research · 12 Aug 2026neutral

Zacks Investment Research reported that the average of Wall Street analysts' price targets suggests a 53.7% potential upside for NovoCure (NVCR), though the article notes the reliability of such metrics is questionable.

Why it matters — NVCR watchers would care because analyst price targets and earnings estimate revisions can influence market sentiment and stock performance.

4 Healthcare Stocks to Watch as Defensive Demand Strengthens

Zacks Investment Research · 7 Aug 2026positive

Zacks Investment Research identified NVCR among healthcare stocks to watch, noting that healthcare's defensive demand is strengthening in 2026 and citing NVCR's improving earnings outlook and steady sector momentum alongside BTSG, HRMY and UNH.

Why it matters — The item highlights NVCR as standing out on an improving earnings outlook and steady sector momentum, which is relevant context for investors tracking the company.

NovoCure (NVCR) Upgraded to Buy: What Does It Mean for the Stock?

Zacks Investment Research · 27 July 2026positive

NovoCure (NVCR) was upgraded to a Zacks Rank #2 (Buy) by Zacks Investment Research, reflecting growing optimism about the company's earnings prospects.

Why it matters — An upgrade to a Buy rating signals increased confidence in NovoCure's earnings outlook, which could influence investor sentiment and the stock's near-term direction.

Wall Street Analysts Believe NovoCure (NVCR) Could Rally 46.63%: Here's is How to Trade

Zacks Investment Research · 27 July 2026positive

A Zacks Investment Research report noted that the mean of analysts' price targets for NovoCure (NVCR) suggests a 46.6% upside, and strong agreement among analysts on raising earnings estimates also points to potential upside.

Why it matters — NVCR watchers would care because analyst price targets and earnings estimate revisions are closely watched indicators that can influence investor sentiment and stock movement.

Unlocking NovoCure (NVCR) International Revenues: Trends, Surprises, and Prospects

Zacks Investment Research · 27 July 2026neutral

Zacks Investment Research published an analysis examining the evolution of NovoCure's overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Why it matters — International revenue trends are a key factor for NVCR watchers assessing the company's global growth trajectory and its influence on analyst expectations.

FAQ

Frequently asked questions about NVCR stock

What is the NVCR stock price forecast for 2026-2027?

The 7 Wall Street analysts covering NovoCure Ltd. have a median 12-month price target of $25, with estimates ranging from $17 to $52. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NVCR stock a buy right now?

Of the 7 analysts covering NovoCure Ltd., 4 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks NovoCure Ltd. 94 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NVCR?

As at 13 Aug 2026, NovoCure Ltd. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (92 of 100).

Will NVCR stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +47.5% from the last close, and Ticker Nerd's factor model ranks NovoCure Ltd. 94 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NVCR stock forecast for 2030?

No analyst covering NovoCure Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NVCR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $52 over the next 12 months.

How has NVCR stock performed over the past year?

NovoCure Ltd. returned +46.2% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does NovoCure Ltd. do?

NovoCure Ltd. is a global oncology company specializing in non-invasive medical devices for the treatment of solid tumor cancers.

What is the latest news on NVCR?

The most recent item we track (Zacks Investment Research, 12 Aug 2026): "Wall Street Analysts Think NovoCure (NVCR) Could Surge 53.68%: Read This Before Placing a Bet". Zacks Investment Research reported that the average of Wall Street analysts' price targets suggests a 53.7% potential upside for NovoCure (NVCR), though the article notes the reliability of such metrics is questionable.

Company

About NovoCure Ltd.

NovoCure Ltd. is a global oncology company specializing in non-invasive medical devices for the treatment of solid tumor cancers. The business is built around its proprietary Tumor Treating Fields therapy, which uses precisely tuned electric fields to disrupt cancer cell division in solid tumors. NovoCure develops, manufactures, and commercializes portable TTFields devices that patients can use at home under the supervision of oncologists. Its key commercial products include Optune Gio, indicated for glioblastoma, and Optune Lua, used in malignant pleural mesothelioma and certain lung cancer settings. The company’s technology is positioned between medical devices and oncology therapeutics, often used alongside standard chemotherapy or immunotherapy to broaden treatment options for patients with aggressive cancers. NovoCure operates across multiple regions including the United States, Germany, Japan, Greater China, and other international markets, generating revenue primarily through therapy fees reimbursed by public and private payers. Founded in 2000 and headquartered in Switzerland with a registered office in Saint Helier, Jersey, NovoCure plays a distinct role in the cancer care market by offering an alternative modality to surgery, radiation, and systemic drug therapies.

CEO Mr. Frank Leonard · 1,605 employees · Switzerland · https://www.novocure.com